Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.

摘要: Objectives To determine the correlation between expression of three DNA repair genes and early failure/clinical outcome stage III colorectal cancer (CRC) patients administrated with FOLFOX-4, including excision cross-complementation group 1 (ERCC1), cross-complementing 2 (ERCC2), X-ray protein (XRCC1). Materials Methods We retrospectively analyzed clinicopathological features ERCC1, ERCC2, XRCC1 expressions by immunohistochemical staining in 180 CRC undergoing curative resection treated FOLFOX-4 chemotherapy to identify predictors postoperative failure. Results Among patients, 44 were classified into failure group, 136 categorized non-early group. A multivariate logistic regression analysis showed that ERCC1 overexpression (P = 0.005), high carcinoembryonic antigen (CEA) levels (P = 0.001) independent failure. Additionally, was not only a predictor but also for disease-free survival (P < 0.001) overall (P < 0.001). However, no predictive roles ERCC2 among these patients. Conclusions ERCC1 is an important administrating adjuvant this marker may help who would benefit from intensive follow-up enhance therapeutic programs. J. Surg. Oncol. 2013; 108:457–464. © 2013 Wiley Periodicals, Inc.